Ursodeoxycholic Acid Market - Size, Share, Trends, and Forecast, 2022 - 2028

Ursodeoxycholic Acid Market - Size, Share, Trends, and Forecast, 2022 - 2028

Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid and is used for dissolving gallstones that are rich in cholesterol. It is also used to improve the flow of bile in primary biliary cirrhosis. UDCA solubilizes cholesterol gallstones, and improves liver function in case of cholestatic diseases. UDCA can be obtained from cholic acid, which is the most abundant and least expensive bile acid available.
Market Dynamics
Factors such as increasing prevalence of gallstones and cystic fibrosis, combined with approval for new indications, is expected to drive market growth over the forecast period. For instance, according to the American Gastroenterological Association 2021 report, gallstones affects 10-15% of the U.S. population annually, which accounts for around 25 million people. In May 2021, IntraBio Ltd. received orphan designation from the European Commission, for ursodeoxycholic acid for the treatment of Niemann-Pick disease. However, the occurrence of possible side effects including nausea, vomiting, itching or dry skin, headache, and sleep disturbances are factors restricting growth of the market.
Key features of the study:
This report provides in-depth analysis of the ursodeoxycholic acid market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ursodeoxycholic acid market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as part of this study include Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global ursodeoxycholic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the ursodeoxycholic acid market
Detailed Segmentation:
Global Ursodeoxycholic Acid Market, By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
Global Ursodeoxycholic Acid Market, By Mode of Extraction:
Synthetic
Biological
Global Ursodeoxycholic Acid Market, By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
Global Ursodeoxycholic Acid Market, By Region:
North America
By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
By Mode of Extraction:
Synthetic
Biological
By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
By Country:
U.S.
Canada
Latin America
By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
By Mode of Extraction:
Synthetic
Biological
By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
By Mode of Extraction:
Synthetic
Biological
By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
By Mode of Extraction:
Synthetic
Biological
By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
By Mode of Extraction:
Synthetic
Biological
By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Dosage Form:
Solid Dosage Form
Liquid Dosage Form
By Mode of Extraction:
Synthetic
Biological
By Application:
Gallstones
Cystic Fibrosis
Liver Cirrhosis
Others
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Dipharma Francis Srl*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
ERREGIERRE S.p.A.
Grindeks
Industria Chimica Emiliana
Mitsubishi Tanabe Pharma Corporation
Zhongshan Belling Biotechnology Co.
Glenmark Pharmaceutical Limited
Abil Chempharma Private Limited
Biotavia Labs Pvt Ltd
Daewoong Bio Inc.
PharmaZell GmbH
Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.